SENTI-301A / Senti Bio, Celest Therap - LARVOL DELTA

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics (GlobeNewswire) - "Senti Biosciences, Inc...announced that the first patient has been dosed in the pilot trial of SN301A in HCC in mainland China in collaboration with Celest Therapeutics (Shanghai) Co. Ltd ('Celest')....The safety and efficacy of SN301A is being evaluated in an investigator-initiated open-label, single-center study (NCT06652243) in adult patients with advanced GPC3-expressing HCC. Three dose levels of SN301A will be administered in cycles, each comprising of 3 weekly doses (Days 0, 7, 14) during a 28-day treatment cycle following a standard lymphodepletion conditioning regimen of fludarabine and cytarabine. Patients may continue to receive multiple cycles of treatment based on their safety and efficacy results."

Trial status • Hepatocellular Cancer

Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights (GlobeNewswire) - "PIPELINE AND CORPORATE HIGHLIGHTS: (i) SENTI-202 for Acute Myeloid Leukemia ('AML'):...The Phase 1 trial focuses on patients with relapsed/refractory AML in the U.S. and Australia. Initial safety and efficacy data readout remains on-track by year-end 2024 and initial durability data is expected to follow in 2025...; (ii) SENTI-301A for HCC:... Celest plans to enroll patients initially in a pilot trial in mainland China and expects to dose the first patient in the fourth quarter of 2024."

New trial • P1 data • Acute Myelogenous Leukemia • Hepatocellular Cancer

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights (GlobeNewswire) - "SENTI-301A for HCC: Senti Bio is developing SENTI-301A to treat solid tumors in China through a strategic collaboration agreement with Celest Therapeutics (Shanghai) Co. Ltd ('Celest'). Celest will enroll patients initially through a pilot trial in mainland China and now expects to dose the first patient in the fourth quarter of 2024."

New trial • Hepatocellular Cancer

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights (GlobeNewswire) - "SENTI-202 for AML:...The Company anticipates the following from the Phase 1 clinical trial: (i) First patient dosed in the second quarter of 2024; (ii) Initial efficacy data by year-end 2024; (iii) Initial durability data in 2025....SENTI-301A for HCC:...Celest plans to enroll patients initially through a pilot trial in mainland China and expects to dose the first patient in the second quarter of 2024."

New P1 trial • New trial • Acute Myelogenous Leukemia • Hepatocellular Cancer

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program (GlobeNewswire) - "The Company outlined the following key strategic decisions:...Continue SENTI-301A program work in China through the partnership with Celest Therapeutics; the first patient is anticipated to be dosed in the first half of 2024."

New trial • Solid Tumor

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China (GlobeNewswire) - "Senti Biosciences...announced a new strategic collaboration with Celest Therapeutics...for the clinical development of SENTI-301A to treat solid tumors in China. Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio. Celest plans to enroll patients initially through a pilot trial in mainland China and expects to enroll the first patient in the first half of 2024. Celest and Senti Bio have the option to expand clinical development of SENTI-301A to Hong Kong, Macau and Taiwan....Under the terms of the collaboration, Senti Bio will be eligible to receive up to $156 million in certain milestone payments, in addition to potential tiered royalty payments....The planned dose finding trial will include 9 patients with advanced glypican 3 ('GPC3')-expressing hepatocellular carcinoma ('HCC') across two dose cohorts."

Licensing / partnership • New trial • Hepatocellular Cancer

SENTI-301A, an off-the-shelf multi-armed preclinical CAR-NK cell therapy, for the treatment of GPC3 expressing tumors (AACR 2023) - "SENTI-301A is a novel off-the-shelf preclinical CAR-NK cell therapy candidate that targets GPC3-expressing tumors in an antigen-specific manner and exhibits increased persistence via crIL-15. We are exploring the potential synergy between SENTI-301A and CPIs to enhance the existing antitumor functions of SENTI-301A. SENTI-301A is planned for clinical development with an investigational new drug application (IND) expected in 2023."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3 • GZMB • IFNG • IL15

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting (GlobeNewswire) - "Senti Biosciences...announced the acceptance of three abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida....Preclinical data will be presented describing the efficacy and safety profile of SENTI-202, a first-in-class logic gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) while sparing the healthy bone marrow....Preclinical data will be presented from SENTI-301A, an off-the-shelf CAR-NK product candidate engineered with a GPC3 CAR and calibrated-release interleukin-15 (crIL-15) targeting GPC3 expressing solid tumors such as hepatocellular carcinomas (HCC)."

Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Liver Cancer • Myelodysplastic Syndrome • Oncology • Solid Tumor

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance (GlobeNewswire) - "Senti Biosciences, Inc...announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors. The Company does not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocellular carcinoma (HCC), on its own at this time; however, the Company believes there is significant market opportunity for SENTI-301A, especially in territories within Asia where HCC is more prevalent than in the United States....With SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell product candidate that is designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow, the Company has commenced IND-enabling studies and remains on track to file an IND application in the second half of 2023."

IND • Pipeline update • Acute Myelogenous Leukemia • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates (GlobeNewswire) - "Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; expected IND filing in 2023.... Senti Biosciences, Inc...reported financial results for the third quarter ended September 30, 2022, and highlighted recent pipeline advances, including an outline for its proposed Phase 1 clinical trial plans for SENTI-202, to include patients with CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)....RECENT PIPELINE HIGHLIGHTS - CAR-NK Cell Oncology Pipeline and Gene Circuit Platform Highlights: SENTI-202....Manufacturing efforts and GMP facility buildout remain on track towards enabling flexible clinical manufacturing of CAR-NK cells in 2023; An IND application for SENTI-202 is expected to be submitted to the U.S. Food and Drug Administration (FDA) in 2023."

Clinical protocol • IND • Pipeline update • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Liver Cancer • Myelodysplastic Syndrome • Oncology • Solid Tumor

Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting (GlobeNewswire) - "Senti Bio...announced three presentations at the American Society of Gene and Cell Therapy (ASGCT) annual meeting being held in Washington D.C., May 16–19, 2022....SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells....SENTI-301 poster presentation highlights optimization of Multi-Arming and Regulator Dial Gene Circuits to improve the cytotoxicity of allogeneic CAR-NK cells and immune stimulation in hepatocellular carcinoma."

Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Liver Cancer • Oncology • Solid Tumor

Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences (GlobeNewswire) - "Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells....ISCT abstract describes scalable, reproducible, cGMP-ready CAR-NK manufacturing process to support planned clinical development of oncology pipeline candidates...Data from this presentation demonstrate that Senti Bio’s CAR-NK cell manufacturing process will likely support translation to GMP clinical manufacturing in support of multiple allogeneic CAR-NK cell therapy products across the Company’s pipeline, including planned clinical development of SENTI-202 for acute myeloid leukemia and SENTI-301 for hepatocellular carcinoma."

Commercial • Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Liver Cancer • Oncology • Solid Tumor

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies (GlobeNewswire) - "Filing an IND, anticipated in 2023, for SENTI-202, a logic-gated allogeneic CAR-NK cell therapy being designed to target and eliminate AML cells while sparing the healthy bone marrow; Filing an IND, anticipated in 2023, for SENTI-301, a multi-armed allogeneic CAR-NK cell therapy being developed for the treatment of HCC."

IND • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Oncology

Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer (Scripintelligence) - "Company Anticipates IND Filing In 2022-2023..."

Financing • IND • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Oncology

Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform (Businesswire) - "Leaps by Bayer and Senti Biosciences, Inc...announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG...SENTI-202 for acute myeloid leukemia (AML), SENTI-301 for hepatocellular carcinoma (HCC), and additional candidates for other undisclosed solid tumor targets...'including starting IND-enabling studies in 2021.'"

Financing • New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor